[EN] BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS<br/>[FR] COMPOSES DE BENZOTHIAZINONE ET DE BENZOXAZINONE
                        
                            
                                申请人:BASF AG
                            
                            
                                公开号:WO2000075139A2
                            
                            
                                公开(公告)日:2000-12-14
                            
                            Q is - N=or CR2; X is S, O or NOR3; Y is-O-, -S-, -SO- or -SO¿2?-; R and R?1¿ are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R2 is H or a substituent; R3 is H, or -C(O)R4; R4 is a substituted or unsubstituted aliphatic or aromatic group; n is an integer from 0 to 1. Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.